


## Receptor phosphorylation is key for agonist-induced internalisation of M<sub>1</sub> muscarinic acetylcholine receptors

M. Scarpa, A. B. Tobin, S. J. Bradley. The Centre for Translational Pharmacology, Institute of Molecular, Cell and Systems Biology, The University of Glasgow, Glasgow, United Kingdom.

**Introduction** M<sub>1</sub> muscarinic acetylcholine receptor (M<sub>1</sub> mAChR) agonists and positive allosteric modulators improve cognition and enhance cholinergic signalling in Alzheimer's disease models<sup>1-3</sup>. However, these ligands can show a wide range of adverse effect liabilities associated with on-target overstimulation of the receptor<sup>4</sup>. Recently, our lab have demonstrated that transgenic mice expressing a phosphorylation-deficient mutant of the M<sub>1</sub> mAChR, are more sensitive to adverse responses, such as seizures, in response to administration of M<sub>1</sub>-selective agonists. We hypothesise that M<sub>1</sub>-agonists stimulating increased phosphorylation and internalisation may be less likely to induce receptor overstimulation and on-target adverse effects. In this study, we aim to understand the role of phosphorylation in agonist-induced internalisation specifically.

**Method** Cell monolayers of CHO cells expressing wild-type (WT) M<sub>1</sub> muscarinic acetylcholine receptors (mAChRs) or the phosphorylation-deficient mutant (PD) where all serine residues in the third intracellular loop and C-terminal tail are mutated to alanine, were stimulated for 0, 5, 15 and 30, 60 and 240 minutes with the muscarinic agonist carbachol (CCh; 100 μM). CCh-treated cells were transferred on ice, washed with ice-cold Krebs-Henseleit buffer and radiolabelled with saturating concentration of [<sup>3</sup>H]-NMS (4 nM) overnight at 4°C to quantify cell surface expression. All data are expressed as means ± S.E.M. of three separate experiments (n=3) and were normalised as percentage of untreated cells for each assay.

**Results** In M<sub>1</sub> mAChR WT cells, four hours of CCh stimulation caused a reduction in cell surface receptors to 58.4% ±2.2% compared to untreated cells, with most of the receptors (29.9% ±7.1%) internalising within the first hour (Fig. 1). In contrast, agonist treatment of cells expressing PD mutant of M<sub>1</sub> AChR caused no change in levels of surface receptors within the first hour of stimulation and 8.4% ±3.4% receptor internalisation after 4 hours, which may be associated with receptor desensitisation or constitutive internalisation rather than agonist-induced internalisation.



**Conclusions** Agonist-induced internalisation of M<sub>1</sub> mAChRs is mediated by receptor phosphorylation and it was prevented when receptor phosphorylation sites were removed. Receptor phosphorylation is crucial for agonist-induced internalisation and is likely contributing to an increased adverse effect liability of M<sub>1</sub>-selective agonists in the M<sub>1</sub> PD mice.

### Reference

- 1 Bodick, N. C. *et al.* (1997). *Archives of Neurology* **54**, 465-473.
- 2 Puri, V., *et al.* (2015). *Behavioural Brain Research* **287**, 96-99.
- 3 Bradley, S. J. *et al.* (2017). *J Clin Invest.* **127**, 487-499.
- 4 Rook, J. M. *et al.* (2017). *ACS Chemical Neuroscience* **8**, 866-883